GlassScriptPhysician profile
Charles S Landers
NPI 1285988576
$2,228.09
in general payments reported to CMS, 2019-2025
26 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.98 · 2022: $168 · 2023: $749 · 2024: $541 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $313.56 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $313.14 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $241.10 | 2022-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $220.78 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $195.31 | 2022-2025 | Veozah |
| Glaxosmithkline, LLC. | $102.07 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Mckesson Medical-Surgical, INC. | $93.50 | 2023 | |
| Myriad Women'S Health, INC. | $88.00 | 2023 | Myrisk |
| Abbvie INC. | $80.62 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $75.74 | 2023-2024 | Quviviq |
| Pfizer INC. | $65.00 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $60.97 | 2022-2023 | Belsomra, Steglujan, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.88 | 2022-2024 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.47 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $47.60 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $44.49 | 2022-2023 | Xarelto |
| Smith+Nephew, INC. | $28.62 | 2021 | |
| Insulet Corporation | $18.95 | 2024 | Omnipod |
| Antares Pharma, INC. | $18.71 | 2023 | Xyosted, Nocdurna, Tlando |
| Organogenesis INC. | $18.36 | 2021 | |
| Sumitomo Pharma America, INC. | $17.49 | 2025 | Gemtesa |
| Abbott Laboratories | $15.82 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $15.71 | 2024 | Rexulti |
| Nevro Corp. | $14.81 | 2023 | Senza |
| Amneal Pharmaceuticals LLC | $13.77 | 2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $13.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Landers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.